Review




Structured Review

INFINIUM Inc infinium genotyping data
Performance measures from the PRS pipeline validation study at the clinical laboratory. PRS pipeline accuracy is assessed as the Pearson correlation between scores derived from PCR-free 30X WGS and those derived from imputed <t> genotyping data </t> (GDA) in the same 70 specimens. Pearson correlation shown in the mean correlation across all ancestry groups tested. PRS pipeline precision (repeatability) is the measure of concordance in PRS scores calculated from the same 70 specimens, run through the pipeline 10 times over the course of two weeks. PRS pipeline precision (reproducibility) is assessed using three samples, each run 6 times end-to-end and then compared in a pairwise manner. The z-score standard deviation is used as a measure of variability. PRS site missingness is the percentage of genomics sites in the original score that are missing from the final imputed dataset. Odds Ratios for high PRS vs Not high pRS are derived from the condition-specific cohorts and calculated by each condition lead group across the ancestries available. Odds ratio information for Obesity/BMI is in preparation for publication by the GIANT consortium.
Infinium Genotyping Data, supplied by INFINIUM Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genotyping+data/infinium+genotyping+data/pmc10275001-101-0-0
Average 90 stars, based on 1 article reviews
infinium genotyping data - by Bioz Stars, 2026-11
90/100 stars

Images

1) Product Images from "Selection, optimization, and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse populations"

Article Title: Selection, optimization, and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse populations

Journal: medRxiv

doi: 10.1101/2023.05.25.23290535

Performance measures from the PRS pipeline validation study at the clinical laboratory. PRS pipeline accuracy is assessed as the Pearson correlation between scores derived from PCR-free 30X WGS and those derived from imputed  genotyping data  (GDA) in the same 70 specimens. Pearson correlation shown in the mean correlation across all ancestry groups tested. PRS pipeline precision (repeatability) is the measure of concordance in PRS scores calculated from the same 70 specimens, run through the pipeline 10 times over the course of two weeks. PRS pipeline precision (reproducibility) is assessed using three samples, each run 6 times end-to-end and then compared in a pairwise manner. The z-score standard deviation is used as a measure of variability. PRS site missingness is the percentage of genomics sites in the original score that are missing from the final imputed dataset. Odds Ratios for high PRS vs Not high pRS are derived from the condition-specific cohorts and calculated by each condition lead group across the ancestries available. Odds ratio information for Obesity/BMI is in preparation for publication by the GIANT consortium.
Figure Legend Snippet: Performance measures from the PRS pipeline validation study at the clinical laboratory. PRS pipeline accuracy is assessed as the Pearson correlation between scores derived from PCR-free 30X WGS and those derived from imputed genotyping data (GDA) in the same 70 specimens. Pearson correlation shown in the mean correlation across all ancestry groups tested. PRS pipeline precision (repeatability) is the measure of concordance in PRS scores calculated from the same 70 specimens, run through the pipeline 10 times over the course of two weeks. PRS pipeline precision (reproducibility) is assessed using three samples, each run 6 times end-to-end and then compared in a pairwise manner. The z-score standard deviation is used as a measure of variability. PRS site missingness is the percentage of genomics sites in the original score that are missing from the final imputed dataset. Odds Ratios for high PRS vs Not high pRS are derived from the condition-specific cohorts and calculated by each condition lead group across the ancestries available. Odds ratio information for Obesity/BMI is in preparation for publication by the GIANT consortium.

Techniques Used: Biomarker Discovery, Derivative Assay, Standard Deviation

Related Articles

Biomarker Discovery:

Article Title: Development of two major resources for pea genomics: the GenoPea 13.2K SNP Array and a high-density, high-resolution consensus genetic map.
Article Snippet: The map lengths obtained in the pre- sent study suggest that by minimizing genotyping errors and missing data, high-density, high-quality Infinium geno- typing data have largely contributed to better distance esti- mations.

Article Title: Selection, optimization, and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse populations
Article Snippet: Infinium genotyping data is compared to this fingerprint as a primary check of sample chain-of-custody fidelity and to preclude sample or plate swaps during lab processing.

Derivative Assay:

Article Title: Development of two major resources for pea genomics: the GenoPea 13.2K SNP Array and a high-density, high-resolution consensus genetic map.
Article Snippet: The map lengths obtained in the pre- sent study suggest that by minimizing genotyping errors and missing data, high-density, high-quality Infinium geno- typing data have largely contributed to better distance esti- mations.

Article Title: Selection, optimization, and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse populations
Article Snippet: Infinium genotyping data is compared to this fingerprint as a primary check of sample chain-of-custody fidelity and to preclude sample or plate swaps during lab processing.

Standard Deviation:

Article Title: Development of two major resources for pea genomics: the GenoPea 13.2K SNP Array and a high-density, high-resolution consensus genetic map.
Article Snippet: The map lengths obtained in the pre- sent study suggest that by minimizing genotyping errors and missing data, high-density, high-quality Infinium geno- typing data have largely contributed to better distance esti- mations.

Article Title: Selection, optimization, and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse populations
Article Snippet: Infinium genotyping data is compared to this fingerprint as a primary check of sample chain-of-custody fidelity and to preclude sample or plate swaps during lab processing.



Similar Products

86
Omics Data Automation genotype data
Genotype Data, supplied by Omics Data Automation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genotyping+data/data+genotype/pm41942696-489-0-26
Average 86 stars, based on 1 article reviews
genotype data - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Neogen genotype data
Genotype Data, supplied by Neogen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genotyping+data/data+genotype/pm41915787-101-8-2
Average 86 stars, based on 1 article reviews
genotype data - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Novogen Inc genotyping data
Genotyping Data, supplied by Novogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genotyping+data/data+genotyping/pm42033919-283-25-12
Average 86 stars, based on 1 article reviews
genotyping data - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Novogen Inc real genotype data
Real Genotype Data, supplied by Novogen Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genotyping+data/data+genotype+real/pm42033919-84-6-14
Average 86 stars, based on 1 article reviews
real genotype data - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Mendeley Ltd genotype data
Genotype Data, supplied by Mendeley Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genotyping+data/data+genotype+simulated/pm41895515-58-0-11
Average 86 stars, based on 1 article reviews
genotype data - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Mendeley Ltd simulated genotype data
Simulated Genotype Data, supplied by Mendeley Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genotyping+data/data+genotype+simulated/pmc12951965-281-0-10
Average 86 stars, based on 1 article reviews
simulated genotype data - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Human Protein Atlas genotype tissue expression gtex data
The mRNA expression levels of CISD1 in human pan-cancer. (A) CISD1 mRNA expression in various human normal <t>tissues.</t> <t>Genotype</t> Tissue Expression <t>(GTEx)</t> data for CISD1 mRNA in human normal tissues were downloaded from The Human Protein Atlas (THPA) and analyzed using GraphPad Prism. (B) CISD1 mRNA expression in various human cancer tissues. The Cancer Genome Atlas (TCGA) data for CISD1 mRNA expression across different cancer types were retrieved from THPA and analyzed using GraphPad Prism. (C) CISD1 mRNA expression levels in tumor tissues were compared with normal tissues across 33 cancer types. Differential expression analysis was conducted using GEPIA2, with a significance threshold of Q < 0.05 (Benjamini-Hochberg correction for multiple testing). Cancer types with significantly increased CISD1 expression are indicated in brown font, while those with significantly decreased expression are in blue font. N = normal tissue, and T = tumor tissue.
Genotype Tissue Expression Gtex Data, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genotyping+data/gtex+portal/pmc12359157-89-0-16
Average 86 stars, based on 1 article reviews
genotype tissue expression gtex data - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Macrogen raw genotyping data
Quality control of the <t>genotyping</t> dataset. ( a ) Distribution of call rates for the initial 296 samples; ( b ) Distribution of call rates for the final 224 samples; ( c ) Gencall scores at the 10th percentile compared to call rates for the initial 296 samples; ( d ) Gencall scores at the 10th percentile for the remaining 224 samples; ( e ) Gencall scores at the 50th percentile for the initial 296 samples; ( f ) Gencall scores at the 50th percentile for the final 224 samples.
Raw Genotyping Data, supplied by Macrogen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genotyping+data/data+raw+sequencing/pmc12550012-96-0-6
Average 86 stars, based on 1 article reviews
raw genotyping data - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

86
Staples genotype data
Quality control of the <t>genotyping</t> dataset. ( a ) Distribution of call rates for the initial 296 samples; ( b ) Distribution of call rates for the final 224 samples; ( c ) Gencall scores at the 10th percentile compared to call rates for the initial 296 samples; ( d ) Gencall scores at the 10th percentile for the remaining 224 samples; ( e ) Gencall scores at the 50th percentile for the initial 296 samples; ( f ) Gencall scores at the 50th percentile for the final 224 samples.
Genotype Data, supplied by Staples, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genotyping+data/data+genotype/pm41072407-79-3-20
Average 86 stars, based on 1 article reviews
genotype data - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

97
Gilead Sciences evaluable genotypic resistance data
Quality control of the <t>genotyping</t> dataset. ( a ) Distribution of call rates for the initial 296 samples; ( b ) Distribution of call rates for the final 224 samples; ( c ) Gencall scores at the 10th percentile compared to call rates for the initial 296 samples; ( d ) Gencall scores at the 10th percentile for the remaining 224 samples; ( e ) Gencall scores at the 50th percentile for the initial 296 samples; ( f ) Gencall scores at the 50th percentile for the final 224 samples.
Evaluable Genotypic Resistance Data, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/genotyping+data/Stribild/fda_document____drugsatfda_docs_slash_label_slash_2014_slash_203100s011lbl-376-58-69
Average 97 stars, based on 1 article reviews
evaluable genotypic resistance data - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

Image Search Results


The mRNA expression levels of CISD1 in human pan-cancer. (A) CISD1 mRNA expression in various human normal tissues. Genotype Tissue Expression (GTEx) data for CISD1 mRNA in human normal tissues were downloaded from The Human Protein Atlas (THPA) and analyzed using GraphPad Prism. (B) CISD1 mRNA expression in various human cancer tissues. The Cancer Genome Atlas (TCGA) data for CISD1 mRNA expression across different cancer types were retrieved from THPA and analyzed using GraphPad Prism. (C) CISD1 mRNA expression levels in tumor tissues were compared with normal tissues across 33 cancer types. Differential expression analysis was conducted using GEPIA2, with a significance threshold of Q < 0.05 (Benjamini-Hochberg correction for multiple testing). Cancer types with significantly increased CISD1 expression are indicated in brown font, while those with significantly decreased expression are in blue font. N = normal tissue, and T = tumor tissue.

Journal: Genes & Diseases

Article Title: Exploring CISD1 as a multifaceted biomarker in cancer: Implications for diagnosis, prognosis, and immunotherapeutic response

doi: 10.1016/j.gendis.2025.101677

Figure Lengend Snippet: The mRNA expression levels of CISD1 in human pan-cancer. (A) CISD1 mRNA expression in various human normal tissues. Genotype Tissue Expression (GTEx) data for CISD1 mRNA in human normal tissues were downloaded from The Human Protein Atlas (THPA) and analyzed using GraphPad Prism. (B) CISD1 mRNA expression in various human cancer tissues. The Cancer Genome Atlas (TCGA) data for CISD1 mRNA expression across different cancer types were retrieved from THPA and analyzed using GraphPad Prism. (C) CISD1 mRNA expression levels in tumor tissues were compared with normal tissues across 33 cancer types. Differential expression analysis was conducted using GEPIA2, with a significance threshold of Q < 0.05 (Benjamini-Hochberg correction for multiple testing). Cancer types with significantly increased CISD1 expression are indicated in brown font, while those with significantly decreased expression are in blue font. N = normal tissue, and T = tumor tissue.

Article Snippet: Genotype Tissue Expression (GTEx) data for CISD1 mRNA in human normal tissues were downloaded from The Human Protein Atlas (THPA) and analyzed using GraphPad Prism. (B) CISD1 mRNA expression in various human cancer tissues.

Techniques: Expressing, Quantitative Proteomics

Quality control of the genotyping dataset. ( a ) Distribution of call rates for the initial 296 samples; ( b ) Distribution of call rates for the final 224 samples; ( c ) Gencall scores at the 10th percentile compared to call rates for the initial 296 samples; ( d ) Gencall scores at the 10th percentile for the remaining 224 samples; ( e ) Gencall scores at the 50th percentile for the initial 296 samples; ( f ) Gencall scores at the 50th percentile for the final 224 samples.

Journal: Scientific Data

Article Title: Genomic landscape of the Great Steppe: Genetic variants in healthy Kazakh individuals

doi: 10.1038/s41597-025-05964-z

Figure Lengend Snippet: Quality control of the genotyping dataset. ( a ) Distribution of call rates for the initial 296 samples; ( b ) Distribution of call rates for the final 224 samples; ( c ) Gencall scores at the 10th percentile compared to call rates for the initial 296 samples; ( d ) Gencall scores at the 10th percentile for the remaining 224 samples; ( e ) Gencall scores at the 50th percentile for the initial 296 samples; ( f ) Gencall scores at the 50th percentile for the final 224 samples.

Article Snippet: Raw genotyping data were downloaded from Macrogen cloud service.

Techniques: Control